title: Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma.
abstract: The discovery of the ubiquitin-proteasome pathway first, and the proteasome inhibitors thereafter were not made in the hope of improving the treatment of malignant diseases. However, bortezomib, the first in class proteasome inhibitor introduced in the clinical practice has contributed to improve the outcome of patients with multiple myeloma, at relapse or disease progression as well as upfront. The results observed in a large randomized trial (APEX) comparing bortezomib and high-dose dexamethasone demonstrated a significant benefit for bortezomib in terms of response rate, progression-free and overall survival. These results led to bortezomib being approved for use in relapsed and/or refractory myeloma patients. Subsequent studies demonstrated that its activity could be enhanced in combination with other drugs; and the next step was to move to the newly diagnosed patient population; in fact, bortezomib-melphalan-prednisone (VMP) is approved as a standard of care for newly diagnosed elderly patients. However, toxicity, especially peripheral neuropathy, as well as the intravenous route required for its administration are the two most significant bortezomib-related issues. To try to reduce the peripheral neuropathy, new guidelines for its management and the introduction of weekly schedules of administration have contributed to significantly decrease its incidence and the subcutaneous administration has been recently introduce to avoid the intravenous (IV) route. Results obtained in phase I/II and III studies have confirmed that subcutaneous administration is feasible and represents an additional step towards the optimization of bortezomib use, resulting in a probably more convenient method than the IV route that is at least as effective.
authors.forename: Marìa-Victoria
authors.initials: MV
authors.lastname: Mateos
authors.forename: Jesús F
authors.initials: JF
authors.lastname: San Miguel
keywords: bortezomib; intravenous and subcutaneous formulations; multiple myeloma
references.citation: N Engl J Med. 2003 Jun 26;348(26):2609-17
references.pmid: 12826635
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804
references.citation: Blood. 2010 Aug 5;116(5):679-86
references.pmid: 20385792
references.citation: N Engl J Med. 1996 Dec 19;335(25):1897-905
references.pmid: 8948566
references.citation: Lancet Oncol. 2011 May;12(5):431-40
references.pmid: 21507715
references.citation: J Clin Oncol. 2010 Dec 1;28(34):5101-9
references.pmid: 20940200
references.citation: J Clin Oncol. 2002 Nov 15;20(22):4420-7
references.pmid: 12431963
references.citation: Haematologica. 2008 Dec;93(12):1908-11
references.pmid: 18768528
references.citation: Cancer Res. 1999 Jun 1;59(11):2615-22
references.pmid: 10363983
references.citation: Blood. 2003 Mar 15;101(6):2377-80
references.pmid: 12424198
references.citation: J Clin Oncol. 2005 Jan 20;23(3):630-9
references.pmid: 15659509
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5713-9
references.pmid: 19786667
references.citation: Blood. 2011 Jul 21;118(3):535-43
references.pmid: 21596852
references.citation: Lancet Oncol. 2010 Oct;11(10):934-41
references.pmid: 20739218
references.citation: Rev Clin Exp Hematol. 2003 Jun;7(2):191-204
references.pmid: 14763162
references.citation: Blood. 2008 Mar 1;111(5):2516-20
references.pmid: 17975015
references.citation: Blood. 2007 Nov 15;110(10):3557-60
references.pmid: 17690257
references.citation: Lancet. 2010 Dec 18;376(9758):2075-85
references.pmid: 21146205
references.citation: N Engl J Med. 2008 Aug 28;359(9):906-17
references.pmid: 18753647
references.citation: Cell. 1994 Sep 9;78(5):773-85
references.pmid: 8087845
references.citation: Br J Haematol. 2004 Oct;127(2):165-72
references.pmid: 15461622
references.citation: J Clin Oncol. 2010 Oct 20;28(30):4621-9
references.pmid: 20823406
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3892-901
references.pmid: 17679727